M2699
马立马司他
≥98% (HPLC), solid, MMP inhibitor
别名:
BB2516, (2S,3R)-N4- [(1S)-2,2-二甲基-1- [（甲氨基）羰基] 丙基]-N1,2-二羟基-3-（2-甲基丙基）丁二酰胺
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H29N3O5
化学文摘社编号:
分子量:
331.41
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
产品名称
马立马司他, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
solid
溶解性
DMSO: ≥20 mg/mL
运输
wet ice
储存温度
−20°C
SMILES字符串
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
InChI
1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
InChI key
OCSMOTCMPXTDND-OUAUKWLOSA-N
基因信息
相关类别
应用
Marimastat已用作下列抑制剂：
- 金属蛋白酶2/9 (MMP2/9)，以研究其对小鼠运动介导的白细胞介素-6 (IL-6)释放的影响
- 金属蛋白酶，测定铜绿假单胞菌培养物中的蛋白酶活性
- 金属蛋白酶10 (MMP10)，研究其对结合MMP10的单克隆抗体H3的影响
生化/生理作用
Marimastat 是一种广谱基质金属蛋白酶 (MMP) 抑制剂
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Timothy W Failes et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)
We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with
Victor A Levin et al.
Journal of neuro-oncology, 78(3), 295-302 (2006-04-26)
Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial
M Ohshima et al.
Journal of dental research, 89(11), 1315-1321 (2010-08-27)
The underlying mechanism and the therapeutic regimen for the transition of reversible gingivitis to irreversible periodontitis are unclear. Since transforming growth factor (TGF)-β has been implicated in differentially regulated gene expression in gingival fibroblasts, we hypothesized that TGF-β signaling is
J Thomas Peterson
Cardiovascular research, 69(3), 677-687 (2006-01-18)
At least 56 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the late 1970's when the first drug discovery program targeting this enzyme family began. Some of these clinical candidates were pursued for multiple indications. However, the
Stefanie K Menzies et al.
Toxicon: X, 14, 100118-100118 (2022-03-25)
Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming by Dispholidus typus (boomslang) results in venom-induced consumption coagulopathy (VICC), whereby highly abundant prothrombin-activating snake venom metalloproteinases (SVMPs) consume clotting factors and deplete fibrinogen. The only available treatment
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持